Olfactory dysfunction and cognitive impairment in age-related neurodegeneration: prevalence related to patient selection, diagnostic criteria and therapeutic treatment of aged clients receiving clinical neurology and community-based care [0.03%]
与临床神经病学和社区保健的患者选择、诊断标准和治疗有关的老年患者的嗅觉障碍和认知功能损害的流行率：老年患者的神经退行性疾病中的嗅觉障碍和认知功能损害
Mark A Babizhayev,Anatoliy I Deyev,Yegor E Yegorov
Mark A Babizhayev
A decrease in olfactory function with age has been attributed to a variety of factors including normal anatomical and physiological changes in aging, surgery, trauma, environmental factors, medications and disease. Olfactory impairment has ...
Georgios Aperis,Christos Paliouras,Eirini Tsampikaki et al.
Georgios Aperis et al.
Anacetrapib is a cholesteryl-ester-transfer-protein (CETP) inhibitor, a new class of experimental drugs in the treatment of primary hypercholesterolemia and dyslipidaemia associated with the metabolic syndrome. One of the major advantages o...
Ulka Vaishampayan
Ulka Vaishampayan
Rhonda L Bitting,John Madden,Andrew J Armstrong
Rhonda L Bitting
The advent of targeted systemic therapies has significantly improved treatment options for patients with metastatic renal cell carcinoma (RCC). Multiple agents that inhibit angiogenesis cell growth and proliferation via the VEGF and mTOR (T...
Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma [0.03%]
mTOR抑制在晚期肾细胞癌治疗中的理论依据
Holleh D Husseinzadeh,Jorge A Garcia
Holleh D Husseinzadeh
Inhibitors of the mammalian target of rapamycin (mTOR) have entered the landscape of treatment for advanced RCC. Their development has been based on their unique biology and their potential to simultaneously inhibit both tumor cell prolifer...
VEGF inhibitors in metastatic renal cell carcinoma: current therapies and future perspective [0.03%]
转移性肾细胞癌的血管生成抑制剂：当前疗法及未来方向
Toni K Choueiri
Toni K Choueiri
Metastatic renal cell carcinoma (RCC) is predominantly refractory to treatment with traditional cytotoxic chemotherapies, and until recently management options were limited to immunotherapy, palliative care, or phase I trials. The past five...
Michel Choueiri,Nizar Tannir,Eric Jonasch
Michel Choueiri
Nephrectomy continues to be the cornerstone of treatment for localized renal cell carcinoma (RCC). Despite undergoing nephrectomy, recurrence of disease remains a concern in many patients, and different medical therapies are being investiga...
Priti Patel,Sandy Srinivas
Priti Patel
The targeted therapies available to treat metastatic kidney cancer include vascular endothelial growth factor (VEGF) inhibitors, bevacizumab, sorafenib, sunitinib, pazopanib, and the mTor inhibitors temsirolimus and everolimus. These agents...
David F McDermott
David F McDermott
In recent years an improved understanding of renal cell carcinoma (RCC) tumor biology has translated into major advancements in the treatment of patients with metastatic RCC. These novel therapies include inhibitors of the vascular endothel...
Petros D Grivas,Bruce G Redman
Petros D Grivas
Renal cell carcinoma (RCC) accounts for 4% of all new cancer cases in males and 3% in females in the US. Compared to other solid tumors, it does not respond to traditional management modalities, such as chemotherapy and radiation therapy. H...